Skip to main content
PMC home page
Neuroscience Bulletin logoLink to Neuroscience Bulletin
. 2014 Apr 15;30(2):233–242. doi: 10.1007/s12264-013-1412-1

Cerebrospinal fluid biomarkers of Alzheimer’s disease

Xiaojing Sui 1, Jianjun Liu 1, Xifei Yang 1,✉
PMCID: PMC5562658  PMID: 24733653

Abstract

Alzheimer’s disease (AD) is a fatal neurodegenerative disorder that takes about a decade to develop, making early diagnosis possible. Clinically, the diagnosis of AD is complicated, costly, and inaccurate, so it is urgent to find specific biomarkers. Due to its multifactorial nature, a panel of biomarkers for the multiple pathologies of AD, such as cerebral amyloidogenesis, neuronal dysfunction, synapse loss, oxidative stress, and inflammation, are most promising for accurate diagnosis. Highly sensitive and high-throughput proteomic techniques can be applied to develop a panel of novel biomarkers for AD. In this review, we discuss the metabolism and diagnostic performance of the well-established core candidate cerebrospinal fluid (CSF) biomarkers (β-amyloid, total tau, and hyperphosphorylated tau). Meanwhile, novel promising CSF biomarkers, especially those identified by proteomics, updated in the last five years are also extensively discussed. Furthermore, we provide perspectives on how biomarker discovery for AD is evolving.

Keywords: Alzheimer’s disease, biomarker, cerebrospinal fluid, β-amyloid, tau, proteomics

References

  • [1].Apostolova LG, Hwang KS, Andrawis JP, Green AE, Babakchanian S, Morra JH, et al. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging. 2010;31:1284–1303. doi: 10.1016/j.neurobiolaging.2010.05.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [2].Wimo A, Prince M. World Alzheimer Report 2010: The Global Economic Impact of Dementia. London: Alzheimer’s Disease International; 2010. [Google Scholar]
  • [3].Kirk A, Kertesz A. On drawing impairment in Alzheimer’s disease. Arch Neurol. 1991;48:73–77. doi: 10.1001/archneur.1991.00530130083024. [DOI] [PubMed] [Google Scholar]
  • [4].Pillon B, Deweer B, Agid Y, Dubois B. Explicit memory in Alzheimer’s, Huntington’s, and Parkinson’s diseases. Arch Neurol. 1993;50:374–379. doi: 10.1001/archneur.1993.00540040036010. [DOI] [PubMed] [Google Scholar]
  • [5].Price BH, Gurvit H, Weintraub S, Geula C, Leimkuhler E, Mesulam M. Neuropsychological patterns and language deficits in 20 consecutive cases of autopsy-confirmedAlzheimer’s disease. Arch Neurol. 1993;50:931–937. doi: 10.1001/archneur.1993.00540090038008. [DOI] [PubMed] [Google Scholar]
  • [6].Galton CJ, Patterson K, Xuereb JH, Hodges JR. Atypical and typical presentations of Alzheimer’s disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain. 2000;123:484–498. doi: 10.1093/brain/123.3.484. [DOI] [PubMed] [Google Scholar]
  • [7].Esteban-Santillan C, Praditsuwan R, Ueda H, Geldmacher DS. Clock drawing test in very mild Alzheimer’s disease. J Am Geriatr Soc. 1998;46:1266–1269. doi: 10.1111/j.1532-5415.1998.tb04543.x. [DOI] [PubMed] [Google Scholar]
  • [8].Greene JD, Baddeley AD, Hodges JR. Analysis of the episodic memory deficit in early Alzheimer’s disease: evidence from the doors and people test. Neuropsychologia. 1996;34:537–551. doi: 10.1016/0028-3932(95)00151-4. [DOI] [PubMed] [Google Scholar]
  • [9].Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297:353–356. doi: 10.1126/science.1072994. [DOI] [PubMed] [Google Scholar]
  • [10].Braak H, Braak E. Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis. Acta Neuropathol. 1996;92:197–201. doi: 10.1007/s004010050508. [DOI] [PubMed] [Google Scholar]
  • [11].Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubuleassociated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A. 1986;83:4913–4917. doi: 10.1073/pnas.83.13.4913. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [12].Pallas M, Camins A. Molecular and biochemical features in Alzheimer’s disease. Curr Pharm Des. 2006;12:4389–4408. doi: 10.2174/138161206778792967. [DOI] [PubMed] [Google Scholar]
  • [13].Pappas BA, Bayley PJ, Bui BK, Hansen LA, Thal LJ. Choline acetyltransferase activity and cognitive domain scores of Alzheimer’s patients. Neurobiol Aging. 2000;21:11–17. doi: 10.1016/S0197-4580(00)00090-7. [DOI] [PubMed] [Google Scholar]
  • [14].Palmer AM, Stratmann GC, Procter AW, Bowen DM. Possible neurotransmitter basis of behavioral changes in Alzheimer’s disease. Ann Neurol. 1988;23:616–620. doi: 10.1002/ana.410230616. [DOI] [PubMed] [Google Scholar]
  • [15].Bobinski M, Wegiel J, Tarnawski M, Bobinski M, Reisberg B, de Leon MJ, et al. Relationships between regional neuronal loss and neurofibrillary changes in the hippocampal formation and duration and severity of Alzheimer disease. J Neuropathol Exp Neurol. 1997;56:414–420. doi: 10.1097/00005072-199704000-00010. [DOI] [PubMed] [Google Scholar]
  • [16].Ray S, Reddy PJ, Jain R, Gollapalli K, Moiyadi A, Srivastava S. Proteomic technologies for the identification of disease biomarkers in serum: Advances and challenges ahead. Proteomics. 2011;11:2139–2161. doi: 10.1002/pmic.201000460. [DOI] [PubMed] [Google Scholar]
  • [17].Price JL, Morris JC. Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol. 1999;45:358–368. doi: 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X. [DOI] [PubMed] [Google Scholar]
  • [18].Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer’s disease. Nature. 2009;461:916–922. doi: 10.1038/nature08538. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [19].Cummings JL. Biomarkers in Alzheimer’s disease drug development. Alzheimers Dement. 2011;7:e13–44. doi: 10.1016/j.jalz.2010.06.004. [DOI] [PubMed] [Google Scholar]
  • [20].Blennow K. CSF biomarkers for Alzheimer’s disease: use in early diagnosis and evaluation of drug treatment. Expert Rev Mol Diagn. 2005;5:661–672. doi: 10.1586/14737159.5.5.661. [DOI] [PubMed] [Google Scholar]
  • [21].Evin G, Weidemann A. Biogenesis and metabolism of Alzheimer’s disease Abeta amyloid peptides. Peptides. 2002;23:1285–1297. doi: 10.1016/S0196-9781(02)00063-3. [DOI] [PubMed] [Google Scholar]
  • [22].Sisodia SS. Beta-amyloid precursor protein cleavage by a membrane-bound protease. Proc Natl Acad Sci U S A. 1992;89:6075–6079. doi: 10.1073/pnas.89.13.6075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [23].Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, et al. A mutation in APP protects against Alzheimer/’s disease and age-related cognitive decline. Nature. 2012;488(7409):96–99. doi: 10.1038/nature11283. [DOI] [PubMed] [Google Scholar]
  • [24].Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987;325:733–736. doi: 10.1038/325733a0. [DOI] [PubMed] [Google Scholar]
  • [25].Masters CL, Cappai R, Barnham KJ, Villemagne VL. Molecular mechanisms for Alzheimer’s disease: implications for neuroimaging and therapeutics. J Neurochem. 2006;97:1700–1725. doi: 10.1111/j.1471-4159.2006.03989.x. [DOI] [PubMed] [Google Scholar]
  • [26].McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann Neurol. 1999;46:860–866. doi: 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M. [DOI] [PubMed] [Google Scholar]
  • [27].Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43) Neuron. 1994;13:45–53. doi: 10.1016/0896-6273(94)90458-8. [DOI] [PubMed] [Google Scholar]
  • [28].Brouillette J, Caillierez R, Zommer N, Alves-Pires C, Benilova I, Blum D, et al. Neurotoxicity and memory deficits induced by soluble low-molecular-weight amyloid-beta1–42 oligomers are revealed in vivo by using a novel animal model. J Neurosci. 2012;32:7852–7861. doi: 10.1523/JNEUROSCI.5901-11.2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [29].Watts JC, Giles K, Grillo SK, Lemus A, DeArmond SJ, Prusiner SB. Bioluminescence imaging of Abeta deposition in bigenic mouse models of Alzheimer’s disease. Proc Natl Acad Sci U S A. 2011;108:2528–2533. doi: 10.1073/pnas.1019034108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [30].Roher AE, Lowenson JD, Clarke S, Woods AS, Cotter RJ, Gowing E, et al. beta-Amyloid-(1–42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:10836–10840. doi: 10.1073/pnas.90.22.10836. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [31].Lannfelt L, Basun H, Vigo-Pelfrey C, Wahlund LO, Winblad B, Lieberburg I, et al. Amyloid beta-peptide in cerebrospinal fluid in individuals with the Swedish Alzheimer amyloid precursor protein mutation. Neurosci Lett. 1995;199:203–206. doi: 10.1016/0304-3940(95)12059-D. [DOI] [PubMed] [Google Scholar]
  • [32].Southwick PC, Yamagata SK, Echols CL, Jr., Higson GJ, Neynaber SA, Parson RE, et al. Assessment of amyloid beta protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer’s disease. J Neurochem. 1996;66:259–265. doi: 10.1046/j.1471-4159.1996.66010259.x. [DOI] [PubMed] [Google Scholar]
  • [33].van Gool WA, Kuiper MA, Walstra GJ, Wolters EC, Bolhuis PA. Concentrations of amyloid beta protein in cerebrospinal fluid of patients with Alzheimer’s disease. Ann Neurol. 1995;37:277–279. doi: 10.1002/ana.410370221. [DOI] [PubMed] [Google Scholar]
  • [34].Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, et al. Cerebrospinal fluid beta-amyloid(1–42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999;56:673–680. doi: 10.1001/archneur.56.6.673. [DOI] [PubMed] [Google Scholar]
  • [35].Blennow K, Hampel H. CSF markers for incipient Alzheimer’s disease. Lancet Neurol. 2003;2:605–613. doi: 10.1016/S1474-4422(03)00530-1. [DOI] [PubMed] [Google Scholar]
  • [36].Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebocontrolled phase I trial. Lancet. 2008;372:216–223. doi: 10.1016/S0140-6736(08)61075-2. [DOI] [PubMed] [Google Scholar]
  • [37].Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol. 2003;60:1696–1702. doi: 10.1001/archneur.60.12.1696. [DOI] [PubMed] [Google Scholar]
  • [38].Engelborghs S, De Vreese K, Van de Casteele T, Vanderstichele H, Van Everbroeck B, Cras P, et al. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging. 2008;29:1143–1159. doi: 10.1016/j.neurobiolaging.2007.02.016. [DOI] [PubMed] [Google Scholar]
  • [39].Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64:343–349. doi: 10.1001/archneur.64.3.noc60123. [DOI] [PubMed] [Google Scholar]
  • [40].Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol. 1998;55:937–945. doi: 10.1001/archneur.55.7.937. [DOI] [PubMed] [Google Scholar]
  • [41].Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, et al. Improved discrimination of AD patients using beta-amyloid(1–42) and tau levels in CSF. Neurology. 1999;52:1555–1562. doi: 10.1212/WNL.52.8.1555. [DOI] [PubMed] [Google Scholar]
  • [42].Ida N, Hartmann T, Pantel J, Schroder J, Zerfass R, Forstl H, et al. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem. 1996;271:22908–22914. doi: 10.1074/jbc.271.37.22908. [DOI] [PubMed] [Google Scholar]
  • [43].Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, et al. Longitudinal study of cerebrospinal fluid levels of tau, A beta1–40, and A beta1–42(43) in Alzheimer’s disease: a study in Japan. Ann Neurol. 1998;44:17–26. doi: 10.1002/ana.410440108. [DOI] [PubMed] [Google Scholar]
  • [44].Kapaki E, Kilidireas K, Paraskevas GP, Michalopoulou M, Patsouris E. Highly increased CSF tau protein and decreased beta-amyloid (1–42) in sporadic CJD: a discrimination from Alzheimer’s disease? J Neurol Neurosurg Psychiatry. 2001;71:401–403. doi: 10.1136/jnnp.71.3.401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [45].Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK, et al. Neurochemical diagnosis of Alzheimer’s dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol Aging. 2004;25:273–281. doi: 10.1016/S0197-4580(03)00086-1. [DOI] [PubMed] [Google Scholar]
  • [46].Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1–40 and 1–42 in Alzheimer disease. Arch Neurol. 2000;57:100–105. doi: 10.1001/archneur.57.1.100. [DOI] [PubMed] [Google Scholar]
  • [47].Skoog I, Davidsson P, Aevarsson O, Vanderstichele H, Vanmechelen E, Blennow K. Cerebrospinal fluid betaamyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord. 2003;15:169–176. doi: 10.1159/000068478. [DOI] [PubMed] [Google Scholar]
  • [48].Sjogren M, Minthon L, Davidsson P, Granerus AK, Clarberg A, Vanderstichele H, et al. CSF levels of tau, beta-amyloid(1–42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm. 2000;107:563–579. doi: 10.1007/s007020070079. [DOI] [PubMed] [Google Scholar]
  • [49].Sjogren M, Davidsson P, Wallin A, Granerus AK, Grundstrom E, Askmark H, et al. Decreased CSF-beta-amyloid 42 in Alzheimer’s disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. Dement Geriatr Cogn Disord. 2002;13:112–118. doi: 10.1159/000048642. [DOI] [PubMed] [Google Scholar]
  • [50].Rosler N, Wichart I, Jellinger KA. Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer’s disease patients. J Neural Transm. 2001;108:231–246. doi: 10.1007/s007020170091. [DOI] [PubMed] [Google Scholar]
  • [51].Andreasen N, Blennow K. beta-amyloid (A beta) protein in cerebrospinal fluid as a biomarker for Alzheimer’s disease. Peptides. 2002;23:1205–1214. doi: 10.1016/S0196-9781(02)00056-6. [DOI] [PubMed] [Google Scholar]
  • [52].Jensen M, Schroder J, Blomberg M, Engvall B, Pantel J, Ida N, et al. Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer’s disease and declines with disease progression. Ann Neurol. 1999;45:504–511. doi: 10.1002/1531-8249(199904)45:4<504::AID-ANA12>3.0.CO;2-9. [DOI] [PubMed] [Google Scholar]
  • [53].Csernansky JG, Miller JP, McKeel D, Morris JC. Relationships among cerebrospinal fluid biomarkers in dementia of the Alzheimer type. Alzheimer Dis Assoc Disord. 2002;16:144–149. doi: 10.1097/00002093-200207000-00003. [DOI] [PubMed] [Google Scholar]
  • [54].Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K. Cerebrospinal fluid levels of total-tau, phosphotau and A beta 42 predicts development of Alzheimer’s disease in patients with mild cognitive impairment. Acta Neurol Scand Suppl. 2003;179:47–51. doi: 10.1034/j.1600-0404.107.s179.9.x. [DOI] [PubMed] [Google Scholar]
  • [55].Shoji M, Matsubara E, Kanai M, Watanabe M, Nakamura T, Tomidokoro Y, et al. Combination assay of CSF tau, A beta 1–40 and A beta 1–42(43) as a biochemical marker of Alzheimer’s disease. J Neurol Sci. 1998;158:134–140. doi: 10.1016/S0022-510X(98)00122-1. [DOI] [PubMed] [Google Scholar]
  • [56].Iqbal K, Alonso AD, Gondal JA, Gong CX, Haque N, Khatoon S, et al. Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach. J Neural Transm Suppl. 2000;59:213–222. doi: 10.1007/978-3-7091-6781-6_22. [DOI] [PubMed] [Google Scholar]
  • [57].Mandelkow EM, Mandelkow E. Tau in Alzheimer’s disease. Trends Cell Biol. 1998;8:425–427. doi: 10.1016/S0962-8924(98)01368-3. [DOI] [PubMed] [Google Scholar]
  • [58].Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, et al. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer’s disease in patients with mild cognitive impairment. Mol Psychiatry. 2004;9:705–710. doi: 10.1038/sj.mp.4001473. [DOI] [PubMed] [Google Scholar]
  • [59].Hu YY, He SS, Wang X, Duan QH, Grundke-Iqbal I, Iqbal K, et al. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer’s disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am J Pathol. 2002;160:1269–1278. doi: 10.1016/S0002-9440(10)62554-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [60].Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302:385–393. doi: 10.1001/jama.2009.1064. [DOI] [PubMed] [Google Scholar]
  • [61].Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry. 2004;61:95–102. doi: 10.1001/archpsyc.61.1.95. [DOI] [PubMed] [Google Scholar]
  • [62].Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, et al. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging. 2009;30:682–690. doi: 10.1016/j.neurobiolaging.2007.08.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [63].Itoh N, Arai H, Urakami K, Ishiguro K, Ohno H, Hampel H, et al. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer’s disease. Ann Neurol. 2001;50:150–156. doi: 10.1002/ana.1054. [DOI] [PubMed] [Google Scholar]
  • [64].Kohnken R, Buerger K, Zinkowski R, Miller C, Kerkman D, DeBernardis J, et al. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer’s disease patients. Neurosci Lett. 2000;287:187–190. doi: 10.1016/S0304-3940(00)01178-2. [DOI] [PubMed] [Google Scholar]
  • [65].Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, et al. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol. 2002;59:1267–1272. doi: 10.1001/archneur.59.8.1267. [DOI] [PubMed] [Google Scholar]
  • [66].Hu YY, He SS, Wang XC, Duan QH, Khatoon S, Iqbal K, et al. Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. Neurosci Lett. 2002;320:156–160. doi: 10.1016/S0304-3940(02)00047-2. [DOI] [PubMed] [Google Scholar]
  • [67].Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403–413. doi: 10.1002/ana.21610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [68].Mulder C, Verwey NA, van der Flier WM, Bouwman FH, Kok A, van Elk EJ, et al. Amyloid-beta(1–42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem. 2010;56:248–253. doi: 10.1373/clinchem.2009.130518. [DOI] [PubMed] [Google Scholar]
  • [69].Qin W, Ho L, Wang J, Peskind E, Pasinetti GM. S100A7, a novel Alzheimer’s disease biomarker with non-amyloidogenic alpha-secretase activity acts via selective promotion of ADAM-10. PLoS One. 2009;4:e4183. doi: 10.1371/journal.pone.0004183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [70].Barao S, Zhou LJ, Adamczuk K, Vanhoutvin T, van Leuven F, Demedts D, et al. BACE1 levels correlate with phosphotau levels in human cerebrospinal fluid. Curr Alzheimer Res. 2013;10:671–678. doi: 10.2174/15672050113109990138. [DOI] [PubMed] [Google Scholar]
  • [71].Mulder SD, van der Flier WM, Verheijen JH, Mulder C, Scheltens P, Blankenstein MA, et al. BACE1 activity in cerebrospinal fluid and its relation to markers of AD Pathology. J Alzheimers Dis. 2010;20:253–260. doi: 10.3233/JAD-2010-1367. [DOI] [PubMed] [Google Scholar]
  • [72].Gao CM, Yam AY, Wang XM, Magdangal E, Salisbury C, Peretz D, et al. A beta 40 Oligomers identified as a potential biomarker for the diagnosis of Alzheimer’s disease. PLoS One 2010, 5. [DOI] [PMC free article] [PubMed]
  • [73].Verwey NA, Kester MI, van der Flier WM, Veerhuis R, Berkhof H, Twaalfhoven H, et al. Additional Value of CSF Amyloid-beta(40) Levels in the Differentiation between FTLD and Control Subjects. J Alzheimers Dis. 2010;20:445–452. doi: 10.3233/JAD-2010-1392. [DOI] [PubMed] [Google Scholar]
  • [74].Bibl M, Gallus M, Welge V, Esselmann H, Wolf S, Ruther E, et al. Cerebrospinal fluid amyloid-beta 2–42 is decreased in Alzheimer’s, but not in frontotemporal dementia. J Neural Transm. 2012;119:805–813. doi: 10.1007/s00702-012-0801-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [75].Ikeuchi T, Hirayama S, Miida T, Fukamachi I, Tokutake T, Ebinuma H, et al. Increased levels of soluble LR11 in cerebrospinal fluid of patients with Alzheimer disease. Dement Geriatr Cogn Disord. 2010;30:28–32. doi: 10.1159/000315539. [DOI] [PubMed] [Google Scholar]
  • [76].Laske C, Stransky E, Hoffmann N, Maetzler W, Straten G, Eschweiler GW, et al. Macrophage colony-stimulating factor (M-CSF) in plasma and CSF of patients with mild cognitive impairment and Alzheimer’s disease. Curr Alzheimer Res. 2010;7:409–414. doi: 10.2174/156720510791383813. [DOI] [PubMed] [Google Scholar]
  • [77].Jiang H, Hampel H, Prvulovic D, Wallin A, Blennow K, Li RN, et al. Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer’s disease. Mol Neurodegener. 2011;6:69. doi: 10.1186/1750-1326-6-69. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [78].Yin GN, Lee HW, Cho JY, Suk K. Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases. Brain Res. 2009;1265:158–170. doi: 10.1016/j.brainres.2009.01.058. [DOI] [PubMed] [Google Scholar]
  • [79].Toledo JB, Korff A, Shaw LM, Trojanowski JQ, Zhang J. CSF alpha-synuclein improves diagnostic and prognostic performance of CSF tau and A beta in Alzheimer’s disease. Acta Neuropathol. 2013;126:683–697. doi: 10.1007/s00401-013-1148-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [80].Santos SM, Garcia-Nimo L, Santos SS, Tavares I, Cocho JA, Castanho M. Neuropeptide kyotorphin (tyrosyl-arginine) has decreased levels in the cerebro-spinal fluid of Alzheimer’sdisease patients: potential diagnostic and pharmacologic alimplications. Front Aging Neurosci 2013, 5. [DOI] [PMC free article] [PubMed]
  • [81].Montine TJ, Peskind ER, Quinn JF, Wilson AM, Montine KS, Galasko D. Increased cerebrospinal fluid F-2-isoprostanes are associated with aging and latent Alzheimer’s disease as identified by biomarkers. Neuromolecular Med. 2011;13:37–43. doi: 10.1007/s12017-010-8126-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [82].Correa JD, Starling D, Teixeira AL, Caramelli P, Silva TA. Chemokines in CSF of Alzheimer’s disease patients. Arq Neuropsiquiatr. 2011;69:455–459. doi: 10.1590/S0004-282X2011000400009. [DOI] [PubMed] [Google Scholar]
  • [83].Craig-Schapiro R, Perrin RJ, Roe CM, Xiong CJ, Carter D, Cairns NJ, et al. YKL-40: A novel prognostic fluid biomarker for preclinical Alzheimer’s disease. Biol Psychiatry. 2010;68:903–912. doi: 10.1016/j.biopsych.2010.08.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [84].Tarawneh R, D’Angelo G, Macy E, Xiong CJ, Carter D, Cairns NJ, et al. Visinin-like Protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol. 2011;70:274–285. doi: 10.1002/ana.22448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [85].Tarawneh R, Lee JM, Ladenson JH, Morris JC, Holtzman DM. CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology. 2012;78:709–719. doi: 10.1212/WNL.0b013e318248e568. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [86].Zenzmaier C, Marksteiner J, Kiefer A, Berger P, Humpel C. Dkk-3 is elevated in CSF and plasma of Alzheimer’s disease patients. J Neurochem. 2009;110:653–661. doi: 10.1111/j.1471-4159.2009.06158.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [87].Kosicek M, Kirsch S, Bene R, Trkanjec Z, Titlic M, Bindila L, et al. Nano-HPLC-MS analysis of phospholipids in cerebrospinal fluid of Alzheimer’s disease patients-a pilot study. Anal Bioanal Chem. 2010;398:2929–2937. doi: 10.1007/s00216-010-4273-8. [DOI] [PubMed] [Google Scholar]
  • [88].Abraham JD, Calvayrac-Pawlowski S, Cobo S, Salvetat N, Vicat G, Molina L, et al. Combined measurement of PEDF, haptoglobin and tau in cerebrospinal fluid improves the diagnostic discrimination between alzheimer’s disease and other dementias. Biomarkers. 2011;16:161–171. doi: 10.3109/1354750X.2010.536995. [DOI] [PubMed] [Google Scholar]
  • [89].Guo LH, Alexopoulos P, Perneczky R. Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci. 2013;263:553–560. doi: 10.1007/s00406-013-0405-4. [DOI] [PubMed] [Google Scholar]
  • [90].Vafadar-Isfahani B, Ball G, Coveney C, Lemetre C, Boocock D, Minthon L, et al. Identification of SPARC-like 1 protein as part of a biomarker panel for Alzheimer’s disease in cerebrospinal fluid. J Alzheimers Dis. 2012;28:625–636. doi: 10.3233/JAD-2011-111505. [DOI] [PubMed] [Google Scholar]
  • [91].Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE, et al. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer’s disease. PLoS One. 2011;6:e16032. doi: 10.1371/journal.pone.0016032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [92].Craig-Schapiro R, Kuhn M, Xiong CJ, Pickering EH, Liu JX, Misko TP, et al. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer’s disease diagnosis and prognosis. PLoS One. 2011;6:e18850. doi: 10.1371/journal.pone.0018850. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [93].Jahn H, Wittke S, Zurbig P, Raedler TJ, Arlt S, Kellmann M, et al. Peptide fingerprinting of Alzheimer’s disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers. PLoS One. 2011;6:e26540. doi: 10.1371/journal.pone.0026540. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Neuroscience Bulletin are provided here courtesy of Springer

RESOURCES